SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Madam C. J. Walker

PatientSarah Walker
Date of birth1976-12-23
IdentifiersMRN HR-ET019-SYN; SSN (made up) 000-19-7062
Document date2026-03-09
AuthorHarriet Okonjo-Bell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week check of potassium and creatinine after starting losartan and empagliflozin, home readings, and the echocardiogram. [S]

History of Present Illness

Madam Walker returns two weeks after starting losartan 50 mg, empagliflozin 10 mg and atorvastatin 20 mg. She has taken them each morning at home time, including on a four-day trip. Her home readings average 144/90, down from 152/96. The morning headaches have stopped. She has had no dizziness, cough, genital itching or muscle aches, and urinates slightly more in the first hours after the empagliflozin. She had a video session with the dietitian and has made a salt-free version of her seasoning blend. Her hepatitis B, hepatitis C and HIV tests were negative, and she has no hepatitis B immunity. The echocardiogram was done this morning. She leaves next week for three weeks of conventions. [S]

ElementDetail
Home blood pressureAverage 144/90 on losartan 50 mg
Side effectsNone
DietDietitian session done; salt-free seasoning blend
Screening testsHepatitis B and C and HIV negative; no hepatitis B immunity

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo dizziness or fainting
NeurologicalNegativeMorning headaches gone
RespiratoryNegativeNo cough
GenitourinaryNegativeNo burning or genital itching
MusculoskeletalNegativeNo muscle aches

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Losartan 50 mg oral tablet, one tablet each morningOne tablet each morning, at the same home time when travelingOral route2026-02-23 to 2026-03-09completedS
Losartan 100 mg oral tablet, one tablet each morningOne tablet each morningOral route2026-03-09activeS
Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgeryOne tablet each morning, with sick-day rulesOral route2026-02-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-02-23activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-09Body height163cmS
2026-03-09Body weight78.2kgS
2026-03-09Body mass index (BMI) [Ratio]29.4kg/m2S
2026-03-09Systolic blood pressure148mm[Hg]S
2026-03-09Diastolic blood pressure92mm[Hg]S
2026-03-09Heart rate78/minS
2026-03-09Respiratory rate16/minS
2026-03-09Body temperature36.7CelS
2026-03-09Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-09Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-09Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-03-09Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-03-09Creatinine [Mass/volume] in Serum or Plasma1.29mg/dL0.59-1.04 mg/dLHighS
2026-03-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M51mL/min/{1.73_m2}60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3aLowS

Physical Exam

Vital signs recorded on 2026-03-09; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 148/92, pulse 78; weight 78.2 kg
CardiovascularRegular rhythm; no ankle swelling
RespiratoryClear

Problems

ProblemClinical statusVerificationCodeProvenance
Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirmresolvedconfirmed R03.0S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks.
Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigatedresolvedconfirmed R80.9S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks.
Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressureactiveconfirmed I12.9S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis.
Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 2021 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6%activeconfirmed N18.31S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease.
Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate)activeconfirmed E78.5S — Synthetic laboratory finding.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationOffice blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings)Every visitCompleted today148/92
Self-managementHome blood pressure readingsTwo readings morning and evening for seven days to confirm and after each change; then twice a week, travel days includedCompleted todayAverage 144/90
ExaminationWeight and BMIEvery visitCompleted today78.2 kg
LaboratoryPotassium, bicarbonate, creatinine and eGFR (CKD-EPI 2021, race-free)Two to four weeks after starting or increasing losartan or empagliflozin; then every six monthsCompleted todayTwo weeks after starting: potassium 4.6, bicarbonate 24 mmol/L; creatinine 1.29 mg/dL, eGFR 51, a 7% rise; repeat two to four weeks after today's increase
LaboratoryUrine albumin-to-creatinine ratioRepeat to confirm; about three months after a treatment change; then every six months for G3a A2Up to date294 mg/g two weeks ago; next at about three months
ImagingEchocardiogramAt diagnosis of stage 2 hypertension or LVH on ECGCompleted todayMild concentric LVH; ejection fraction 60%
LaboratoryLipid panel and ALT4 to 12 weeks after starting a statin, then yearlyUp to dateAtorvastatin started two weeks ago; panel at the next visit
Medication safetyMedicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zonesEvery visitCompleted todayNo dizziness, cough, genital itching or muscle aches; doses taken at home time when traveling; sick-day card in her bag
Self-managementSodium and diet counselingEvery visitCompleted todayDietitian session done; salt-free seasoning; ordering strategies for banquets
LaboratoryHepatitis B, hepatitis C and HIV testsOnce, with the kidney evaluationCompleted todayAll negative; no hepatitis B immunity, so vaccination is planned

Goal progress:

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026)

Follow-up: Potassium and creatinine two to four weeks after the losartan increase. Review in about seven weeks with the urine albumin, kidney function and lipids. Call for dizziness, fainting, or vomiting or diarrhea (hold losartan and empagliflozin). Next scheduled visit 2026-04-27: eleven-week review: home readings on maximum losartan, urine albumin, kidney function after a recent gastroenteritis, lipids on atorvastatin. [S]